1. Home
  2. DLTH vs IPHA Comparison

DLTH vs IPHA Comparison

Compare DLTH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Duluth Holdings Inc. Class B

DLTH

Duluth Holdings Inc. Class B

HOLD

Current Price

$3.05

Market Cap

121.7M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.48

Market Cap

131.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLTH
IPHA
Founded
1989
1999
Country
United States
France
Employees
N/A
163
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.7M
131.4M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
DLTH
IPHA
Price
$3.05
$1.48
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$7.00
$5.75
AVG Volume (30 Days)
68.2K
21.0K
Earning Date
06-04-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
64.12
N/A
EPS
N/A
N/A
Revenue
$565,184,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$2.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$1.18
52 Week High
$4.66
$2.63

Technical Indicators

Market Signals
Indicator
DLTH
IPHA
Relative Strength Index (RSI) 42.68 51.68
Support Level $2.76 $1.35
Resistance Level $3.31 $1.57
Average True Range (ATR) 0.20 0.08
MACD -0.06 0.00
Stochastic Oscillator 6.00 59.09

Price Performance

Historical Comparison
DLTH
IPHA

About DLTH Duluth Holdings Inc. Class B

Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: